News
Long-term results from the phase 2 OVARIO trial (NCT03326193) highlight the effectiveness of niraparib plus bevacizumab as maintenance therapy in patients with advanced ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback